ArticleAmerican journal of translational research2023
E-cadherin and FGFR3 are risk factors determining prognosis of patients with bladder urothelial carcinoma.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the diagnostic value of the combined detection of E-cadherin and FGFR3 in patients with bladder urothelial carcinoma and their correlation with patient prognosis.
methodsThe study retrospectively analyzed the case data of 96 patients with bladder urothelial carcinoma treated at the Yixing Guanlin Hospital from June 2018 to June 2020. Tumor tissue of each patient and matched healthy tissue were collected for immunohistochemical staining. Differences in FGFR3 and E-cadherin expression were identified between tumor and healthy tissues. The influence of clinical characteristics on the recurrence was analyzed using a univariate analysis. Then, a multivariate logistic regression analysis was performed to analyze the risk factors for recurrence in patients with bladder urothelial carcinoma. The diagnostic value of FGFR3, E-cadherin and their combination for disease recurrence and prognosis was analyzed. The correlation of FGFR3 and E-cadherin expression with disease recurrence was discussed.
resultsThe positive expression of FGFR3 in the cancer tissues was significantly higher than that in the adjacent tissue, while the positive expression of E-cadherin showed the opposite (P<0.05). Logistic regression analysis showed that tumor size, TNM stage, pathological grade, FGFR3 and E-cadherin were risk factors for the recurrence of bladder urothelial carcinoma (P<0.05). The area under the curve of FGFR3 combined with E-cadherin in evaluating prognosis and recurrence was 0.957. Correlation analysis revealed that FGFR3 was significantly and positively correlated with the patients' prognostic recurrence while E-cadherin was negatively correlated with it.
conclusionFGFR3 and E-cadherin are risk factors affecting the prognosis of patients with bladder urothelial carcinoma, and they are associated with the outcome of bladder cancer.
Indexed as
Identifiers
36915751PMC10006759W4324129909What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.